BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9168075)

  • 21. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women.
    Miyoshi Y; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2003 Jun; 9(6):2229-33. PubMed ID: 12796390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Level of total cholesterol in serum of patients with breast cancer treated with tamoxifen].
    Wojtacki J; Dziewulska-Bokiniec A
    Pol Tyg Lek; 1993 Jun 7-14; 48(23-24):505-6. PubMed ID: 8170824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mechanism of hormone-sensitive breast cancer progression on antiestrogen therapy. Implications for treatment and protocol planning.
    Pommier RF; Woltering EA; Keenan EJ; Fletcher WS
    Arch Surg; 1987 Nov; 122(11):1311-6. PubMed ID: 2960297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels.
    Bannink EM; van Sassen C; van Buuren S; de Jong FH; Lequin M; Mulder PG; de Muinck Keizer-Schrama SM
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):265-73. PubMed ID: 19200215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Plasma estrogen level in patients with cervical cancer].
    Zheng Y
    Zhonghua Zhong Liu Za Zhi; 1990 Nov; 12(6):404-5. PubMed ID: 2076633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.
    Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
    Menopause; 2009; 16(1):30-6. PubMed ID: 18820592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
    Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
    J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increases in serum estrogen levels during major illness are caused by increased peripheral aromatization.
    Spratt DI; Morton JR; Kramer RS; Mayo SW; Longcope C; Vary CP
    Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E631-8. PubMed ID: 16670151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.
    Morris KT; Toth-Fejel S; Schmidt J; Fletcher WS; Pommier RF
    Surgery; 2001 Dec; 130(6):947-53. PubMed ID: 11742322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian cysts in women receiving tamoxifen for breast cancer.
    Mourits MJ; de Vries EG; Willemse PH; ten Hoor KA; Hollema H; Sluiter WJ; de Bruijn HW; van der Zee AG
    Br J Cancer; 1999 Apr; 79(11-12):1761-4. PubMed ID: 10206289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benign and malignant breast disease: initial study results of serum and breast fluid analyses of endogenous estrogens.
    Ernster VL; Wrensch MR; Petrakis NL; King EB; Miike R; Murai J; Goodson WH; Siiteri PK
    J Natl Cancer Inst; 1987 Nov; 79(5):949-60. PubMed ID: 3479643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adrenal function under long-term raloxifene administration.
    Genazzani AR; Lombardi I; Borgioli G; di Bono I; Casarosa E; Gambacciani M; Palumbo M; Genazzani AD; Luisi M
    Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study.
    Hermelink K; Henschel V; Untch M; Bauerfeind I; Lux MP; Munzel K
    Cancer; 2008 Nov; 113(9):2431-9. PubMed ID: 18823033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
    Eliassen AH; Missmer SA; Tworoger SS; Spiegelman D; Barbieri RL; Dowsett M; Hankinson SE
    J Natl Cancer Inst; 2006 Oct; 98(19):1406-15. PubMed ID: 17018787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of obesity to blood estrogens.
    Zumoff B
    Cancer Res; 1982 Aug; 42(8 Suppl):3289s-3294s. PubMed ID: 7083189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrine treatment of breast cancer: effects upon intratumoral estrone sulfate metabolism and peripheral steroid levels.
    Carlström K; Pousette A; Rannevik G; Sköldefors H; Theve NO; Wilking N
    Breast Cancer Res Treat; 1986; 7 Suppl():S107-9. PubMed ID: 2943337
    [No Abstract]   [Full Text] [Related]  

  • 38. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
    Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
    Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
    Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
    Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.